Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.72 |
| ▸ | CCR3 | P51677 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002203 | 0.89 | HRH1 (0.75) | HRH1CCR3KCNH2 | |
| SCHEMBL5001970 | 0.84 | HRH1 (0.79) | HRH1CCR3KCNH2 | |
| SCHEMBL4970161 | 0.84 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5002565 | 0.83 | HRH1 (0.73) | HRH1CCR3KCNH2 | |
| SCHEMBL4967114 | 0.83 | HRH1 (0.83) | HRH1CCR3KCNH2 | |
| SCHEMBL18841131 | 0.82 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL4968313 | 0.81 | HRH1 (0.81) | HRH1CCR3KCNH2 | |
| SCHEMBL5972206 | 0.81 | HRH1 (0.76) | HRH1CCR3KCNH2 | |
| SCHEMBL4966352 | 0.81 | HRH1 (0.81) | HRH1CCR3KCNH2 | |
| SCHEMBL4998300 | 0.81 | HRH1 (1.00) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| EP-1735298-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | AstraZeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097775-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | HRH1 51/4885CCR3 1/4885KCNH2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.